XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-28 | Q2 2026 | 0.30 | 0.30 | +0.00% | $243.6M | ➖ Inline | +0.73% | -4.34% | +0.45% |
| 2026-04-28 | Q1 2026 | 0.16 | 0.27 | +68.75% | $214.3M | ✅ Beat | +0.00% | +5.37% | -5.59% |
| 2026-02-24 |
| Q4 2025 |
| 0.35 |
| 0.17 |
| -51.43% |
| $202.1M |
| ❌ Miss |
| -2.91% |
| +4.30% |
| +7.54% |
| 2025-10-28 | Q3 2025 | 0.35 | 0.23 | -34.29% | $180.9M | ❌ Miss | — | — | — |
| 2025-07-29 | Q2 2025 | 0.21 | 0.23 | +9.52% | $156.8M | ✅ Beat | +2.55% | +8.89% | +10.31% |
| 2025-04-29 | Q1 2025 | 0.28 | 0.11 | -60.71% | $137.8M | ❌ Miss | — | — | — |
| 2025-02-25 | Q4 2024 | 0.13 | -0.12 | -192.31% | $122.5M | ❌ Miss | — | — | — |
| 2024-10-29 | Q3 2024 | 0.03 | -0.18 | -700.00% | $112.2M | ❌ Miss | — | — | — |
Showing last 8 quarters.